TABLE 1

Demographic and clinical characteristics of patients treated with delamanid under compassionate use

Subjects n78
Age years32 (8–59)
Sex
 Female24 (31)
 Male54 (69)
Weight kg54 (24–83)
Region
 Western Europe3 (4)
 Eastern Europe40 (51)
 Asia18 (23)
 Africa17 (22)
Disease type
 Pulmonary disease alone76 (97)
 Pulmonary and extrapulmonary disease2 (3)
Cavitary disease
 None or unknown42 (54)
 Yes36 (46)
Resistance type
 MDR-TB8 (10)
 Pre-XDR-TB26 (33)
 XDR-TB44 (56)
History of prior TB treatment
 No14 (18)
 Yes64 (82)
Comorbidities
 HIV co-infection12 (15)
 HCV co-infection11 (14)
 HBV co-infection3 (4)
 Diabetes mellitus6 (8)
Baseline culture status
 Negative13 (17)
 Positive65 (83)
Culture status at 24 weeks#
 Negative53 (80)
 Positive11 (17)
 Contaminated1 (2)
 Pending1 (2)
Drugs used in optimised background regimens#
 Linezolid60 (91)
 Clofazimine50 (76)
 Fluoroquinolones45 (68)
 Aminoglycosides or capreomycin45 (68)
 Carbapenems33 (50)
 Bedaquiline12 (18)
Active drugs in regimens (excluding delamanid)#
 Negative culture status at 24 weeks3.3 (0–5)
 Positive culture status at 24 weeks2.3 (0–5)

Data are presented as mean (range) or n (%), unless otherwise stated. MDR-TB: multidrug-resistant tuberculosis; XDR-TB: extensively drug-resistant tuberculosis; TB: tuberculosis; HCV: hepatitis C virus; HBV: hepatitis B virus. #: among delamanid treatment completers, n=66.